DE60231316D1 - VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTEN - Google Patents
VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTENInfo
- Publication number
- DE60231316D1 DE60231316D1 DE60231316T DE60231316T DE60231316D1 DE 60231316 D1 DE60231316 D1 DE 60231316D1 DE 60231316 T DE60231316 T DE 60231316T DE 60231316 T DE60231316 T DE 60231316T DE 60231316 D1 DE60231316 D1 DE 60231316D1
- Authority
- DE
- Germany
- Prior art keywords
- receptor
- ox2ra
- cd200ra
- fcepsilonri
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003213 activating effect Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32918201P | 2001-10-12 | 2001-10-12 | |
PCT/US2002/032711 WO2003030835A2 (en) | 2001-10-12 | 2002-10-11 | Use of bispecific antibodies to regulate immune responses |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60231316D1 true DE60231316D1 (de) | 2009-04-09 |
Family
ID=23284239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60231316T Expired - Lifetime DE60231316D1 (de) | 2001-10-12 | 2002-10-11 | VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTEN |
Country Status (10)
Country | Link |
---|---|
US (2) | US20030077282A1 (de) |
EP (3) | EP2316485A1 (de) |
JP (2) | JP4381140B2 (de) |
AT (1) | ATE423571T1 (de) |
AU (1) | AU2002334997A1 (de) |
CA (1) | CA2462883A1 (de) |
DE (1) | DE60231316D1 (de) |
ES (1) | ES2321701T3 (de) |
MX (1) | MXPA04003291A (de) |
WO (1) | WO2003030835A2 (de) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060084082A1 (en) * | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
US6989248B2 (en) * | 1999-05-06 | 2006-01-24 | The Trustees Of Columbia University In The City Of New York | Methods of use of compounds which inhibit the stem cell signaling pathway |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
US8231878B2 (en) * | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US20090081199A1 (en) * | 2001-03-20 | 2009-03-26 | Bioxell S.P.A. | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
CA2342376C (en) * | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US7265208B2 (en) * | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
US20030077282A1 (en) * | 2001-10-12 | 2003-04-24 | Bigler Michael Eric | Use of bispecific antibodies to regulate immune responses |
EP1482973B1 (de) * | 2002-03-15 | 2009-08-19 | Schering Corporation | Verfahren zur modulierung von cd200-rezeptoren |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US8946387B2 (en) * | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8187593B2 (en) * | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8193318B2 (en) * | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8044180B2 (en) * | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8530627B2 (en) * | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
JP2006524039A (ja) * | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
BG65715B1 (bg) * | 2003-09-04 | 2009-08-31 | Чавдар ВАСИЛЕВ | Средство за селективно подтискане на патологични днк - специфични в клетки |
US20050169870A1 (en) * | 2004-02-02 | 2005-08-04 | Schering Corporation | Methods of modulating CD200 |
WO2005077065A2 (en) * | 2004-02-09 | 2005-08-25 | The Regents Of The University Of California | Selective high-affinity polydentate ligands and methods of making such |
ES2375481T3 (es) * | 2004-03-30 | 2012-03-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos. |
KR101297146B1 (ko) | 2004-05-10 | 2013-08-21 | 마크로제닉스, 인크. | 인간화 FcγRIIB 특이적 항체 및 그의 사용 방법 |
KR20120133403A (ko) | 2004-06-01 | 2012-12-10 | 도만티스 리미티드 | 증강된 혈청 반감기를 가지는 이특이성 융합 항체 |
US7655229B2 (en) * | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
EP1674479A1 (de) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulierung von Fc-gamma-Rezeptoren zur Optimierung einer Immunotherapie |
BG65954B1 (bg) * | 2005-01-05 | 2010-07-30 | Чавдар ВАСИЛЕВ | Средство за селективно подтискане активността на патологични автореактивни в-клетки |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) * | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
CA2605024C (en) * | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
ES2417065T3 (es) * | 2005-04-26 | 2013-08-05 | Trion Pharma Gmbh | Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer |
GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
SI1912675T1 (sl) | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
DK1919503T3 (en) * | 2005-08-10 | 2014-12-15 | Macrogenics Inc | Identification and preparation of antibodies with variant fc regions and methods of use thereof |
AU2007226752A1 (en) * | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
EP2021029B1 (de) * | 2006-05-26 | 2014-06-11 | MacroGenics, Inc. | Humanisierte fc-gamma-riib-spezifische antikörper und verfahren zu ihrer anwendung |
MX363905B (es) | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
EP2029173B1 (de) * | 2006-06-26 | 2016-07-20 | MacroGenics, Inc. | Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung |
WO2008002933A2 (en) * | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
WO2009151717A2 (en) * | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
US8795667B2 (en) * | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
WO2009085920A1 (en) * | 2007-12-20 | 2009-07-09 | Schering Corporation | Fdf03 antibodies and uses thereof |
CA2720368C (en) | 2008-04-02 | 2017-08-22 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
EP2132228B1 (de) | 2008-04-11 | 2011-06-22 | Emergent Product Development Seattle, LLC | Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon |
ES2613844T3 (es) | 2008-04-21 | 2017-05-26 | Lawrence Livermore National Security, Llc | Ligandos polidentados de alta afinidad selectivos y métodos para producirlos |
ES2675730T3 (es) * | 2008-06-04 | 2018-07-12 | Macrogenics, Inc. | Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos |
WO2010048424A1 (en) * | 2008-10-22 | 2010-04-29 | The Regents Of The University Of Michigan | Methods, compositions, and kits for diagnosing, monitoring, and treating disease |
US20120121588A1 (en) * | 2009-05-20 | 2012-05-17 | Schering Corporation | Modulation of pilr receptors to treat sepsis |
WO2011044368A1 (en) | 2009-10-07 | 2011-04-14 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
CA2791658C (en) | 2010-03-04 | 2019-10-01 | Macrogenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
JP5964300B2 (ja) | 2010-08-02 | 2016-08-03 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディおよびその使用 |
JP5850943B2 (ja) * | 2010-11-24 | 2016-02-03 | ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズGovernment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 狼瘡を治療又は予防するための組成物及び方法 |
US10017762B2 (en) | 2010-11-24 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating or preventing lupus |
JP6145088B2 (ja) | 2011-05-21 | 2017-06-07 | マクロジェニクス,インコーポレーテッド | 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用 |
WO2013013029A1 (en) | 2011-07-19 | 2013-01-24 | The Board Of Trustees Of The University Of Illinois | Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US9663568B2 (en) | 2012-02-15 | 2017-05-30 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
ES2640268T3 (es) | 2012-02-15 | 2017-11-02 | Novo Nordisk A/S | Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1) |
BR112014022692A8 (pt) | 2012-03-14 | 2021-07-20 | Regeneron Pharma | molécula de ligação de antígeno multiespecífica |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
WO2014159940A1 (en) | 2013-03-14 | 2014-10-02 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
US20160115231A1 (en) | 2013-05-21 | 2016-04-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
EP2840091A1 (de) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser |
EP2839842A1 (de) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon |
WO2015106311A1 (en) | 2014-01-17 | 2015-07-23 | Minomic International Ltd. | Cell surface prostate cancer antigen for diagnosis |
KR20240029114A (ko) | 2014-07-17 | 2024-03-05 | 노보 노르디스크 에이/에스 | 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발 |
EP3201227A4 (de) | 2014-09-29 | 2018-04-18 | Duke University | Bispezifische moleküle mit einem hiv-1-hüll-targeting-arm |
NZ737726A (en) | 2015-07-06 | 2023-03-31 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
SG11201808979UA (en) | 2016-04-15 | 2018-11-29 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
BR112019022752A2 (pt) | 2017-08-03 | 2020-05-19 | Alector Llc | anticorpos anti-trem2 e métodos de uso dos mesmos |
AR117566A1 (es) | 2018-04-02 | 2021-08-18 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1 y sus usos |
CN110872356B (zh) * | 2018-09-03 | 2023-06-13 | 广西慧宝源健康产业有限公司 | 双特异性抗体及其使用方法 |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2046920B1 (de) | 1969-06-19 | 1974-05-03 | Citizen Watch Co Ltd | |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
EP0088994B1 (de) | 1982-03-15 | 1991-06-19 | Schering Corporation | Hybride DNS, damit hergestellte Bindungszusammensetzung und Verfahren dafür |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
ATE59966T1 (de) | 1983-09-26 | 1991-02-15 | Ehrenfeld Udo | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4954617A (en) * | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
FI105320B (fi) * | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
DE3814079A1 (de) | 1988-04-26 | 1989-11-09 | Bayer Ag | Sinterformkoerper auf basis von aluminiumtitanat, verfahren zu ihrer herstellung sowie deren verwendung |
US6197298B1 (en) * | 1991-04-19 | 2001-03-06 | Tanox, Inc. | Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
EP0861891A1 (de) * | 1996-12-31 | 1998-09-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Verbindungen zur Modulation zellnegativer Regulierungen und deren biologische Anwendungen |
US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
DK1032662T3 (da) * | 1997-11-07 | 2006-07-03 | Trillium Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulation |
US6955811B2 (en) * | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
US20020155604A1 (en) * | 1998-02-19 | 2002-10-24 | Jeffrey A. Ledbetter | Compositions and methods for regulating lymphocyte activation |
JP2002521055A (ja) * | 1998-07-30 | 2002-07-16 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 98個のヒト分泌タンパク質 |
US7118743B2 (en) * | 1998-11-17 | 2006-10-10 | Tanox, Inc. | Bispecific molecules cross-linking ITIM and ITAM for therapy |
AU1727500A (en) * | 1998-11-17 | 2000-06-05 | Tanox, Inc. | Bispecific molecules cross-linking itim and itam for therapy |
US20020192215A1 (en) * | 1999-04-13 | 2002-12-19 | Schering Corporation, A New Jersey Corporation | Novel uses of mammalian OX2 protein and related reagents |
WO2000061171A2 (en) | 1999-04-13 | 2000-10-19 | Schering Corporation | Uses of mammalian ox2 protein and related reagents |
CA2372549A1 (en) | 1999-05-13 | 2000-11-23 | Medical Research Council | Ox2 receptor homologs |
EP1240183A2 (de) | 1999-11-15 | 2002-09-18 | Schering Corporation | Gene die spezifisch in menschlichen dendritischen zellen exprimiert werden |
CA2429579A1 (en) * | 2000-11-22 | 2002-05-30 | Trillium Therapeutics Inc. | Truncated cd200 |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US9249229B2 (en) * | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
AU2001247543A1 (en) | 2001-03-16 | 2003-09-02 | Tanox, Inc. | Bispecific molecules cross-linking itim and itam for therapy of allergies |
US7186818B2 (en) * | 2001-04-26 | 2007-03-06 | Immunex Corporation | DNA encoding soluble variants of human OX2 receptors |
WO2002095030A2 (en) * | 2001-05-24 | 2002-11-28 | Trillium Therapeutics Inc. | Modulation of cd200 receptors |
US20030077282A1 (en) * | 2001-10-12 | 2003-04-24 | Bigler Michael Eric | Use of bispecific antibodies to regulate immune responses |
US20040126777A1 (en) * | 2002-01-28 | 2004-07-01 | Bhatt Ramesh Rajani | Lp mammalian proteins; related reagents |
EP1482973B1 (de) * | 2002-03-15 | 2009-08-19 | Schering Corporation | Verfahren zur modulierung von cd200-rezeptoren |
JP4763282B2 (ja) * | 2002-06-07 | 2011-08-31 | トリリウム セラピューティクス インコーポレーティッド | 骨発生の調節方法 |
JP2006512396A (ja) | 2002-12-27 | 2006-04-13 | シェーリング コーポレイション | 免疫寛容を誘導および維持する方法 |
US20070244052A1 (en) * | 2003-12-19 | 2007-10-18 | Schering Corporation | Methods for Identifying Agonists or Antagonists of CD200R Signaling Molecules and Methods of Using the Same |
US20050169870A1 (en) * | 2004-02-02 | 2005-08-04 | Schering Corporation | Methods of modulating CD200 |
-
2002
- 2002-10-11 US US10/270,084 patent/US20030077282A1/en not_active Abandoned
- 2002-10-11 AT AT02801055T patent/ATE423571T1/de not_active IP Right Cessation
- 2002-10-11 WO PCT/US2002/032711 patent/WO2003030835A2/en active Application Filing
- 2002-10-11 AU AU2002334997A patent/AU2002334997A1/en not_active Abandoned
- 2002-10-11 EP EP10182926A patent/EP2316485A1/de not_active Withdrawn
- 2002-10-11 ES ES02801055T patent/ES2321701T3/es not_active Expired - Lifetime
- 2002-10-11 MX MXPA04003291A patent/MXPA04003291A/es active IP Right Grant
- 2002-10-11 CA CA002462883A patent/CA2462883A1/en not_active Abandoned
- 2002-10-11 EP EP09151125A patent/EP2072059A1/de not_active Withdrawn
- 2002-10-11 JP JP2003533869A patent/JP4381140B2/ja not_active Expired - Lifetime
- 2002-10-11 EP EP02801055A patent/EP1439857B1/de not_active Expired - Lifetime
- 2002-10-11 DE DE60231316T patent/DE60231316D1/de not_active Expired - Lifetime
-
2009
- 2009-08-12 JP JP2009187524A patent/JP2009256389A/ja active Pending
-
2010
- 2010-05-25 US US12/787,044 patent/US8236309B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20100330034A1 (en) | 2010-12-30 |
US20030077282A1 (en) | 2003-04-24 |
CA2462883A1 (en) | 2003-04-17 |
ATE423571T1 (de) | 2009-03-15 |
US8236309B2 (en) | 2012-08-07 |
EP2316485A1 (de) | 2011-05-04 |
MXPA04003291A (es) | 2004-07-23 |
WO2003030835A2 (en) | 2003-04-17 |
ES2321701T3 (es) | 2009-06-10 |
EP1439857A4 (de) | 2004-11-17 |
AU2002334997A1 (en) | 2003-04-22 |
EP2072059A1 (de) | 2009-06-24 |
EP1439857A2 (de) | 2004-07-28 |
EP1439857B1 (de) | 2009-02-25 |
JP4381140B2 (ja) | 2009-12-09 |
WO2003030835A3 (en) | 2003-10-09 |
JP2009256389A (ja) | 2009-11-05 |
JP2006501130A (ja) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60231316D1 (de) | VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTEN | |
DK1461428T3 (da) | Fremgangsmåde til at fremstille hybridantistoffer | |
CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
CY1110759T1 (el) | Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων | |
ATE490275T1 (de) | Antikörper gegen interleukin-22 und verwendungen dafür | |
NO20054351L (no) | Monoklonalt antistoff og hybridom som produserer dette | |
DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
ATE483472T1 (de) | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten | |
ATE530195T1 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
ATE378403T1 (de) | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern | |
ATE470676T1 (de) | Anti-vegf-2 antikörper | |
ATE554107T1 (de) | Als therapeutika geeignete monovalente antikörperfragmente | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
TW200510459A (en) | RG1 antibodies and uses thereof | |
EA200601386A1 (ru) | ИММУНОГЛОБУЛИНЫ ПРОТИВ АНТИГЕНА EpCAM | |
ATE309331T1 (de) | Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung | |
DE602004026872D1 (de) | Anti-hgf-r-antikörper und deren verwendung | |
CY1110144T1 (el) | Αντισωματα για την ταυτοποιηση και/ή την απομονωση τουλαχιστον ενος κυτταρικου πληθυσμου ο οποιος επιλεγεται απο την ομαδα την περιλαμβανουσα αιμοποιητικα βλαστοκυτταρα, νευρικα βλαστοκυτταρα, νευρικα αρχεγονα κυτταρα, μεσεγχυματικα βλαστοκυτταρα και μεσεγχυματικα αρχεγονα κυτταρα | |
UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
ATE481422T1 (de) | Modulieren von immunantworten | |
HK1154904A1 (zh) | 天然 抗體及其抑制劑 | |
EE200500012A (et) | Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks | |
DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
DK0840620T3 (da) | IL-8-antagonister til behandling af astma | |
IL165088A0 (en) | Transgenic ungulates capable of human antibody production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |